Unlearn Stock
HealthTechLooking to sell Unlearn stock or options?
Unlearn develops machine-learning models that generate digital twins to populate intelligent control arms in clinical trials. By using AI to create synthetic patient data, the company's technology speeds up clinical studies by supplementing control groups. This approach reduces the time needed to develop new medications, allowing healthcare companies to deliver life-saving therapies to patients more swiftly.
Investors Include:
8VC, Necessary Ventures, EPIC Ventures, Mubadala Capital, DCVC Bio, Insight Partners, Parkway Venture Capital, DCVC, Eisai Innovation, Altimeter Capital Management, Alumni Ventures, Wittington Ventures, Radical Ventures.